On the other hand, amongst the compounds that deplete mutant p53, Hsp90 inhibitors (81–83), HDAC inhibitors (116–118), ATO (119–121), and DSF (92, 93, 122) are under clinical trials for cancer therapy. Here, HDAC9 is linked to cancer.